SIGA Technologies (SIGA) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SIGA Technologies (SIGA) has outperformed Upstream Bio (UPB) over the past year, losing 60.4% versus a loss of 76.0%. Upstream Bio is the larger company by market cap ($249.2 million vs $235.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SIGA | UPB |
|---|---|---|
| Share price | $3.28 | $4.55 |
| Market cap | $235.67M | $249.21M |
| 1-day change | +0.61% | -1.30% |
| YTD return | -46.32% | -83.24% |
| 1-year return | -60.39% | -75.95% |
| 5-year return | -53.87% | — |
| Forward P/E | 3.04 | — |
| EPS (TTM) | $-0.04 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.55 | $33.68 |
| 52-week low | $2.83 | $4.37 |
| Distance from 52-week high | -61.64% | -86.49% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +584.40% |
| Average volume | 726.50K | 610.08K |
| Shares outstanding | 71.85M | 54.77M |
| Employees | 49 | 75 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SIGA has outperformed UPB by 15.6 percentage points over the past year.
- The two companies sit in different sectors: SIGA Technologies in Health Care and Upstream Bio in Healthcare.
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
SIGA vs UPB FAQ
Which is bigger, SIGA Technologies or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $249.21M compared with $235.67M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, SIGA or UPB?
SIGA returned -60.39% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are SIGA Technologies and Upstream Bio in the same industry?
No. SIGA Technologies is in the Health Care sector, while Upstream Bio is in Healthcare.